Séverine Guiu

3.7k total citations
78 papers, 1.9k citations indexed

About

Séverine Guiu is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Séverine Guiu has authored 78 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 63 papers in Oncology, 38 papers in Cancer Research and 27 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Séverine Guiu's work include Breast Cancer Treatment Studies (31 papers), HER2/EGFR in Cancer Research (24 papers) and Cancer Treatment and Pharmacology (17 papers). Séverine Guiu is often cited by papers focused on Breast Cancer Treatment Studies (31 papers), HER2/EGFR in Cancer Research (24 papers) and Cancer Treatment and Pharmacology (17 papers). Séverine Guiu collaborates with scholars based in France, United States and Switzerland. Séverine Guiu's co-authors include William Jacot, Boris Guiu, D. Krausé, Patrick Hillon, François Ghiringhelli, P. Fumoleau, Florence Boissière‐Michot, Sylvain Ladoire, Caroline Mollévi and Jean–Pierre Cercueil and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Gut.

In The Last Decade

Séverine Guiu

73 papers receiving 1.9k citations

Peers

Countries citing papers authored by Séverine Guiu

Since Specialization

Citations

This map shows the geographic impact of Séverine Guiu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Séverine Guiu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Séverine Guiu more than expected).

Fields of papers citing papers by Séverine Guiu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Séverine Guiu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Séverine Guiu. The network helps show where Séverine Guiu may publish in the future.

Co-authorship network of co-authors of Séverine Guiu

This figure shows the co-authorship network connecting the top 25 collaborators of Séverine Guiu. A scholar is included among the top collaborators of Séverine Guiu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Séverine Guiu. Séverine Guiu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Temporal evolution of breast cancer brain metastases treatments and outcomes 2025 ·npj Breast Cancer ·Michele Bottosso, Gaia Griguolo, Séverine Guiu, (unknown), Caroline Bailleux, Federica Miglietta, (unknown), (unknown), Jean-Marc Ferrero, (unknown), Cristina Falci, (unknown), Carlo Alberto Giorgi, Alessandro Parisi, Grazia Maria Vernaci, Fabio Girardi, William Jacot, (unknown), Amélie Darlix, Valentina Guarneri	0
2	Prognostic Value of Trop‐2 Expression in Nonmetastatic Triple‐Negative Breast Cancer and Correlation With Emerging Biomarkers 2025 ·Cancer Medicine ·William Jacot, Marie‐Christine Chateau, Simon Thézenas, Séverine Guiu, Nelly Firmin, Virginie Lafont, Gwendal Lazennec, Charles Theillet, Florence Boissière‐Michot	3
3	CDK4/6 inhibitor-induced liver injury: Clinical phenotypes and role of corticosteroid treatment 2024 ·JHEP Reports ·Lucy Meunier, Eléonora De Martin, Bénédicte Delire, William Jacot, Séverine Guiu, (unknown), Dominique Larrey, Yves Horsmans	9
4	Prognostic value of tertiary lymphoid structures in triple-negative breast cancer: integrated analysis with the tumor microenvironment and clinicopathological features 2024 ·Frontiers in Immunology ·Florence Boissière‐Michot, Marie‐Christine Chateau, Simon Thézenas, Virginie Lafont, Evelyne Lopez‐Crapez, Priyanka Sharma, Angélique Bobrie, Pascal Roger, Séverine Guiu, William Jacot	2
5	Anti‐cathepsin D immunotherapy triggers both innate and adaptive anti‐tumour immunity in breast cancer 2023 ·British Journal of Pharmacology ·(unknown), Aude Mallavialle, Julien Faget, Lindsay B. Alcaraz, Marion Lapierre, (unknown), Valérie Laurent‐Matha, (unknown), Marta Jarlier, Pierre Martineau, Pascal Roger, Séverine Guiu, Thierry Chardès, Emmanuelle Liaudet‐Coopman	9
6	First evidence of AXL expression on circulating tumor cells in metastatic breast cancer patients: A proof‐of‐concept study 2023 ·Cancer Medicine ·(unknown), Zahra Eslami‐S, (unknown), (unknown), (unknown), Angélique Bobrie, Véronique D’Hondt, Séverine Guiu, Keerthi Kurma, Laure Cayrefourcq, William Jacot, Catherine Alix‐Panabières	6
7	Experience of patients with metastatic breast cancer in France: results of the 2021 RÉALITÉS survey and comparison with 2015 results 2023 ·ONCOLOGIE ·Jean‐Sébastien Frenel, Séverine Guiu, (unknown), (unknown), Claudia Lefeuvre‐Plesse, (unknown)	0
8	SPARC in cancer‐associated fibroblasts is an independent poor prognostic factor in non‐metastatic triple‐negative breast cancer and exhibits pro‐tumor activity 2022 ·International Journal of Cancer ·Lindsay B. Alcaraz, Aude Mallavialle, Caroline Mollévi, Florence Boissière‐Michot, (unknown), Joëlle Simony-Lafontaine, Valérie Laurent‐Matha, Thierry Chardès, William Jacot, Andrei Turtoï, Pascal Roger, Séverine Guiu, Emmanuelle Liaudet‐Coopman	19
9	Pharmacokinetic Variability Drives Palbociclib-Induced Neutropenia in Metastatic Breast Cancer Patients: Drug–Drug Interactions Are the Usual Suspects 2022 ·Pharmaceutics ·Fanny Leenhardt, Frédéric Fiteni, (unknown), (unknown), Séverine Guiu, Nelly Firmin, Stéphane Pouderoux, Marie Viala, Gérald Lossaint, C. Gautier, Caroline Mollévi, (unknown), Céline Gongora, (unknown), Alexandre Evrard, William Jacot	9
10	Prognostic Value of HER2-Low Expression in Non-Metastatic Triple-Negative Breast Cancer and Correlation with Other Biomarkers 2021 ·Cancers ·William Jacot, Aurélie Maran-Gonzalez, (unknown), (unknown), Caroline Mollévi, Séverine Guiu, Florence Boissière‐Michot, José Ramos	83
11	Clinicopathological Correlates of γδ T Cell Infiltration in Triple-Negative Breast Cancer 2021 ·Cancers ·Florence Boissière‐Michot, (unknown), Caroline Mollévi, Séverine Guiu, Evelyne Lopez‐Crapez, José Ramos, Nathalie Bonnefoy, Virginie Lafont, William Jacot	20
12	BRCA1 Promoter Hypermethylation is Associated with Good Prognosis and Chemosensitivity in Triple-Negative Breast Cancer 2020 ·Cancers ·William Jacot, Evelyne Lopez‐Crapez, Caroline Mollévi, Florence Boissière‐Michot, Joëlle Simony-Lafontaine, Alexandre Ho-Pun-Cheung, (unknown), Charles Theillet, Antoinette Lemoine, Raphaël Saffroy, Pierre‐Jean Lamy, Séverine Guiu	28
13	Inflammatory Blood Markers as Prognostic and Predictive Factors in Early Breast Cancer Patients Receiving Neoadjuvant Chemotherapy 2020 ·Cancers ·(unknown), Simon Thézenas, Aurélie Maran-Gonzalez, Pierre‐Emmanuel Colombo, William Jacot, Séverine Guiu	16
14	Co-Expression of Androgen Receptor and Cathepsin D Defines a Triple-Negative Breast Cancer Subgroup with Poorer Overall Survival 2020 ·Cancers ·(unknown), Lindsay B. Alcaraz, Caroline Mollévi, Aude Mallavialle, William Jacot, Florence Boissière‐Michot, Joëlle Simony-Lafontaine, Valérie Laurent‐Matha, Pascal Roger, Emmanuelle Liaudet‐Coopman, Séverine Guiu	18
15	<p>Decision of Adjuvant Systemic Treatment in HR+ HER2- Early Invasive Breast Cancer: Which Biomarkers Could Help?</p> 2019 ·Cancer Management and Research ·(unknown), Aurélie Maran-Gonzalez, Marie Viala, Nelly Firmin, Véronique D’Hondt, Marian Gutowski, C. Bourgier, William Jacot, Séverine Guiu	4
16	Anti-HER2 therapy efficacy in HER2-negative metastatic breast cancer with HER2-amplified circulating tumor cells: results of the CirCe T-DM1 trial 2017 ·Annals of Oncology ·(unknown), Paul Cottu, Coraline Dubot, Laurence Venat‐Bouvet, Alain Lortholary, Hugues Bourgeois, (unknown), (unknown), (unknown), Marc Espié, Séverine Guiu, Véronique D’Hondt, Véronique Dièras, (unknown), (unknown), Frédérique Berger, J-Y Pierga, William Jacot	9
17	Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases 2016 ·Breast Cancer Research and Treatment ·William Jacot, Elvire Pons‐Tostivint, Jean‐Sébastien Frenel, Séverine Guiu, Christelle Lévy, Pierre-Étienne Heudel, Thomas Bachelot, Véronique D’Hondt, Amélie Darlix, Nelly Firmin, Gilles Romieu, Simon Thézenas, Florence Dalenc	79
18	18F-FDG PET/CT provides powerful prognostic stratification in the primary staging of large breast cancer when compared with conventional explorations 2013 ·European Journal of Nuclear Medicine and Molecular Imaging ·Alexandre Cochet, Inna Dygai‐Cochet, Jean‐Marc Riedinger, Olivier Humbert, Alina Berriolo-Riedinger, Michel Toubeau, Séverine Guiu, Charles Coutant, Bruno Coudert, P. Fumoleau, François Brunotte	62
19	Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement 2012 ·Annals of Oncology ·Séverine Guiu, Stefan Michiels, Fabrice André, Javier Cortés, Carsten Denkert, Angelo Di Leo, Bryan T. Hennessy, Thérese Sørlie, Christos Sotiriou, Nicholas C. Turner, Marc J. van de Vijver, Giuseppe Viale, Sherene Loi, Jorge S. Reis‐Filho	221
20	Bevacizumab/Irinotecan. Un nouveau traitement actif dans les gliomes de haut grade récidivants : résultats préliminaires d’une étude multicentrique de l’Anocef 2008 ·Revue Neurologique ·Séverine Guiu, Sophie Taillibert, Olivier Chinot, Luc Taillandier, Jérôme Honnorat, Pierre‐Yves Dietrich, (unknown), J.-S. Guillamo, Boris Guiu, (unknown), (unknown), Anne C. M. Thiébaut, Stéphanie Cartalat‐Carel, (unknown), P. Fumoleau, Annick Desjardins, Khê Hoang‐Xuan, Bruno Chauffert	39

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact